Q-omics provides the consensus-scored MAP11 profile across patient tissues and cancer cell-line models. MAP11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAP11 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MAP11 protein abundance shows 21,153 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where MAP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP11 survival associations across molecular data types. MAP11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP11 RNA expression–survival associations across cancer types. High MAP11 expression shows unfavorable associations in KIRC, ACC, LGG, COAD and KICH, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAP11 RNA expression.
This table summarizes MAP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP11 shows higher tumor expression in HNSC, LUAD, LIHC, STAD, BRCA and UCEC. The HNSC box plot shows higher MAP11 RNA expression in tumor versus normal tissue (log2 FC = +0.913, t-test p < 0.001).
This table shows molecular features associated with MAP11 in patient tissues and cancer cell lines. In patient samples, MAP11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
